Cosmo Pharmaceuticals N.V.
CMOPF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $266,788 | $92,780 | $102,089 | $65,074 |
| % Growth | 187.5% | -9.1% | 56.9% | – |
| Cost of Goods Sold | $19,865 | $39,340 | $18,762 | $15,140 |
| Gross Profit | $246,923 | $53,440 | $83,327 | $49,934 |
| % Margin | 92.6% | 57.6% | 81.6% | 76.7% |
| R&D Expenses | $373 | $18,811 | $15,525 | $11,357 |
| G&A Expenses | $6,459 | $5,301 | $3,131 | $2,469 |
| SG&A Expenses | $7,412 | $5,331 | $3,550 | $2,808 |
| Sales & Mktg Exp. | $953 | $30 | $419 | $339 |
| Other Operating Expenses | $90,256 | $23,152 | $36,195 | $6,831 |
| Operating Expenses | $98,041 | $47,294 | $55,270 | $20,996 |
| Operating Income | $148,882 | $6,146 | $28,057 | $11,101 |
| % Margin | 55.8% | 6.6% | 27.5% | 17.1% |
| Other Income/Exp. Net | $4,485 | -$4,614 | -$3,584 | $12,902 |
| Pre-Tax Income | $153,367 | $1,532 | $24,473 | $24,003 |
| Tax Expense | $20,176 | $6,264 | $6,968 | $2,330 |
| Net Income | $133,236 | -$4,932 | $17,225 | $21,672 |
| % Margin | 49.9% | -5.3% | 16.9% | 33.3% |
| EPS | 8.15 | -0.31 | 1.05 | 1.29 |
| % Growth | 2,729% | -129.5% | -18.6% | – |
| EPS Diluted | 8.12 | -0.31 | 1.05 | 1.28 |
| Weighted Avg Shares Out | 16,359 | 16,105 | 16,425 | 16,842 |
| Weighted Avg Shares Out Dil | 16,418 | 16,105 | 16,425 | 16,904 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1,751 | $3,950 | $2,941 | $3,062 |
| Interest Expense | $126 | $8,526 | $9,159 | $8,990 |
| Depreciation & Amortization | $12,285 | $13,553 | $13,112 | $6,710 |
| EBITDA | $165,705 | $19,699 | $46,744 | $17,811 |
| % Margin | 62.1% | 21.2% | 45.8% | 27.4% |